David Wing-Hang Lam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Wing-Hang Lam has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Yun Feng
Beth Israel Medical Center, Albert Einstein College of Medicine
4 shared publicationsAdrienne M. Fleckman
Albert Einstein College of Medicine, Beth Israel Medical Center
1 shared publicationAnu Lala
Icahn School of Medicine at Mount Sinai, Mount Sinai Heart, New York, USA
1 shared publication- Carlos G. Santos-Gallego
Atherothrombosis Research Unit, Icahn School of Medicine At Mount Sinai, One Gustave L. Levy Pl, New York, USA
1 shared publication - Donna Mancini
Icahn School of Medicine at Mount Sinai, Mount Sinai Heart, New York, USA
1 shared publication - Farah Atallah-Lajam
Icahn School of Medicine at Mount Sinai, Mount Sinai Heart, New York, USA
1 shared publication
Latest Publications
- 12 July 2025
- Published by Springer Nature
- p. 361-375
Integrative Approach in Diabetes
- 15 June 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (1) , 155-164
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure (HF). This syndrome is associated with an elevated morbi-mortality, and effective therapies are urgently needed. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the first pharmacological class that has demonstrated to reduce hospitalization and cardiovascular mortality in large clinical trials in HFpEF. Furthermore, the dual SGLT 1/2 inhibitor sotagliflozin has shown a reduction in cardiovascular outcomes in diabetic HF patients, regardless of ejection fraction Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) Trial, and prevents the development of HF in patients with diabetes and chronic kidney disease Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial. The major objective of the Sotagliflozin in Heart Failure With Preserved Ejection Fraction Patients (SOTA-P-CARDIA) trial (NCT05562063) is to investigate whether the observed cardiorenal benefits of sotagliflozin in HF patients with diabetes can be extended to a non-diabetic population. The SOTA-P-CARDIA is a prospective, randomized, double-blinded, placebo-controlled study that will randomize non-diabetic patients with the universal definition of HFpEF (ejection fraction > 50% assessed the day of randomization). Qualifying patients will be randomized, in blocks of 4, to receive either sotagliflozin or placebo for a period of 6 months. The primary outcome is changes in left ventricular mass by cardiac magnetic resonance from randomization to end of the study between the groups. Secondary end points include changes in peak VO2; myocardial mechanics, interstitial myocardial fibrosis, and volume of epicardial adipose tissue; distance in the 6-min walk test; and quality of life. Finally, the authors expect that this trial will help to clarify the potential benefits of the use of sotagliflozin in non-diabetic HFpEF patients.
- 15 June 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (1) , 155-164
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure (HF). This syndrome is associated with an elevated morbi-mortality, and effective therapies are urgently needed. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the first pharmacological class that has demonstrated to reduce hospitalization and cardiovascular mortality in large clinical trials in HFpEF. Furthermore, the dual SGLT 1/2 inhibitor sotagliflozin has shown a reduction in cardiovascular outcomes in diabetic HF patients, regardless of ejection fraction Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) Trial, and prevents the development of HF in patients with diabetes and chronic kidney disease Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial. The major objective of the Sotagliflozin in Heart Failure With Preserved Ejection Fraction Patients (SOTA-P-CARDIA) trial (NCT05562063) is to investigate whether the observed cardiorenal benefits of sotagliflozin in HF patients with diabetes can be extended to a non-diabetic population. The SOTA-P-CARDIA is a prospective, randomized, double-blinded, placebo-controlled study that will randomize non-diabetic patients with the universal definition of HFpEF (ejection fraction > 50% assessed the day of randomization). Qualifying patients will be randomized, in blocks of 4, to receive either sotagliflozin or placebo for a period of 6 months. The primary outcome is changes in left ventricular mass by cardiac magnetic resonance from randomization to end of the study between the groups. Secondary end points include changes in peak VO2; myocardial mechanics, interstitial myocardial fibrosis, and volume of epicardial adipose tissue; distance in the 6-min walk test; and quality of life. Finally, the authors expect that this trial will help to clarify the potential benefits of the use of sotagliflozin in non-diabetic HFpEF patients.
- 1 January 2023
- Published by Springer Nature
- p. 235-252
Inpatient Management of Diabetes During Pregnancy
- 1 January 2023
- Published by Springer Nature
- p. 235-252
Inpatient Management of Diabetes During Pregnancy
- 21 July 2017
- Published by Springer Nature
- p. 349-365
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
- 21 July 2017
- Published by Springer Nature
- p. 349-365
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
- 7 October 2016
- Published by Springer Nature
- p. 1-17
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
- 7 October 2016
- Published by Springer Nature
- p. 1-17
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
- 30 July 2016
- Published by Springer Nature
- p. 1-17
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
- 30 July 2016
- Published by Springer Nature
- p. 1-17
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
- 1 January 2015
- Published by Springer Nature
- p. 1-17
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State
- 1 January 2015
- Published by Springer Nature
- p. 1-17
Acute Hyperglycemic Syndromes: Diabetic Ketoacidosis and the Hyperosmolar State